Melissa G. Mendez

Melissa G. Mendez

Auto-generated profile, based on publicly available information

Melissa G. Mendez

Genomic Sciences, GlaxoSmithKline, Collegeville, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
RGRobert D. Goldman
Robert D. Goldman
DSDale K. Shumaker
Dale K. Shumaker
MEMichael R. Erdos
Michael R. Erdos
MEMaria Eriksson
Maria Eriksson
AGAnne E. Goldman
Anne E. Goldman
FCFrancis S. Collins
Francis S. Collins
Hutchinson–Gilford progeria syndrome (HGPS) is a premature aging disorder, commonly caused by a point mutation in the lamin A gene that results in a protein lacking 50 aa near the C terminus, denoted LAΔ50. Here we show by light and electron microscopy that HGPS is associated with significant changes in nuclear shape, including lobulation of the nuclear envelope, thickening of the nuclear lamina, loss of peripheral heterochromatin, and clustering of nuclear pores. These structural defects worsen as HGPS cells age in culture, and their severity correlates with an apparent increase in LAΔ50. Introduction of LAΔ50 into normal cells by transfection or protein injection induces the same changes. We hypothesize that these alterations in nuclear structure are due to a concentration-dependent dominant-negative effect of LAΔ50, leading to the disruption of lamin-related functions ranging from the maintenance of nuclear shape to regulation of gene expression and DNA replication.

22 January 2010 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MMMelissa G. Mendez
Melissa G. Mendez
SKShin‐Ichiro Kojima
Shin‐Ichiro Kojima
RGRobert D. Goldman
Robert D. Goldman
Vimentin is used widely as a marker of the epithelial to mesenchymal transitions (EMTs) that take place during embryogenesis and metastasis, yet the functional implications of the expression of this type III intermediate filament (IF) protein are poorly understood. Using form factor analysis and quantitative Western blotting of normal, metastatic, and vimentin‐null cell lines, we show that the level of expression of vimentin IFs (VIFs) correlates with mesenchymal cell shape and motile behavior. The reorganization of VIFs caused by expressing a dominant‐negative mutant or by silencing vimentin with shRNA (neither of which alter microtubule or microfilament assembly) causes mesenchymal cells to adopt epithelial shapes. Following the microinjection of vimentin or transfection with vimentin cDNA, epithelial cells rapidly adopt mesenchymal shapes coincident with VIF assembly. These shape transitions are accompanied by a loss of desmosomal contacts, an increase in cell motility, and a significant increase in focal adhesion dynamics. Our results demonstrate that VIFs play a predominant role in the changes in shape, adhesion, and motility that occur during the EMT.—Mendez, M. G., Kojima, S.‐I., Goldman, R. D. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 24, 1838–1851 (2010). www.fasebj.org

28 April 2023 in Nature Reviews Drug Discovery
Verified
Journal Article
Open access
PDF file
BSBram Van de Sande
Bram Van de Sande
JLJoon Sang Lee
Joon Sang Lee
EMEuphemia Mutasa-Gottgens
Euphemia Mutasa-Gottgens
BNBart Naughton
Bart Naughton
WBWendi Bacon
Wendi Bacon
EFEdgardo Ferran
Edgardo Ferran
Single-cell technologies, particularly single-cell RNA sequencing (scRNA-seq) methods, together with associated computational tools and the growing availability of public data resources, are transforming drug discovery and development. New opportunities are emerging in target identification owing to improved disease understanding through cell subtyping, and highly multiplexed functional genomics screens incorporating scRNA-seq are enhancing target credentialling and prioritization. ScRNA-seq is also aiding the selection of relevant preclinical disease models and providing new insights into drug mechanisms of action. In clinical development, scRNA-seq can inform decision-making via improved biomarker identification for patient stratification and more precise monitoring of drug response and disease progression. Here, we illustrate how scRNA-seq methods are being applied in key steps in drug discovery and development, and discuss ongoing challenges for their implementation in the pharmaceutical industry.

15 April 2011 in Molecular Biology of the Cell
Verified
Journal Article
Open access
BHBrian T. Helfand
Brian T. Helfand
MMMelissa G. Mendez
Melissa G. Mendez
SMS. N. Prasanna Murthy
S. N. Prasanna Murthy
DSDale K. Shumaker
Dale K. Shumaker
BGBoris Grin
Boris Grin
RGRobert D. Goldman
Robert D. Goldman
Vimentin intermediate filaments (VIF) extend throughout the rear and perinuclear regions of migrating fibroblasts, but only nonfilamentous vimentin particles are present in lamellipodial regions. In contrast, VIF networks extend to the entire cell periphery in serum-starved or nonmotile fibroblasts. Upon serum addition or activation of Rac1, VIF are rapidly phosphorylated at Ser-38, a p21-activated kinase phosphorylation site. This phosphorylation of vimentin is coincident with VIF disassembly at and retraction from the cell surface where lamellipodia form. Furthermore, local induction of photoactivatable Rac1 or the microinjection of a vimentin mimetic peptide (2B2) disassemble VIF at sites where lamellipodia subsequently form. When vimentin organization is disrupted by a dominant-negative mutant or by silencing, there is a loss of polarity, as evidenced by the formation of lamellipodia encircling the entire cell, as well as reduced cell motility. These findings demonstrate an antagonistic relationship between VIF and the formation of lamellipodia.

1 July 2014 in Biophysical Journal
Verified
Journal Article
Closed access
MMM.G. Mendez
M.G. Mendez
DRD. Restle
D. Restle
PJPaul Janmey
Paul Janmey

1 July 2011 in Molecular Biology of the Cell
Verified
Journal Article
Open access
ONOxana E. Nekrasova
Oxana E. Nekrasova
MMMelissa G. Mendez
Melissa G. Mendez
ICIvan S. Chernoivanenko
Ivan S. Chernoivanenko
Pyotr Tyurin-KuzminPyotr Tyurin-Kuzmin
Pyotr Tyurin-Kuzmin
EKEdward R. Kuczmarski
Edward R. Kuczmarski
AMAlexander Minin
Alexander Minin
Interactions with vimentin intermediate filaments (VimIFs) affect the motility, distribution, and anchorage of mitochondria. In cells lacking VimIFs or in which VimIF organization is disrupted, the motility of mitochondria is increased relative to control cells that express normal VimIF networks. Expression of wild-type VimIF in vimentin-null cells causes mitochondrial motility to return to normal (slower) rates. In contrast, expressing vimentin with mutations in the mid-region of the N-terminal non–α-helical domain (deletions of residues 41–96 or 45–70, or substitution of Pro-57 with Arg) did not inhibit mitochondrial motility even though these mutants retain their ability to assemble into VimIFs in vivo. It was also found that a vimentin peptide consisting of residues 41–94 localizes to mitochondria. Taken together, these data suggest that VimIFs bind directly or indirectly to mitochondria and anchor them within the cytoplasm.